About JW Therapeutics

JW Therapeutics (HKEX: 2126) is a biotechnology company dedicated to advancing innovative cell immunotherapies.

Founded in 2016 in partnership with Juno Therapeutics*, the Company combines global expertise in cell therapy development with China's manufacturing capabilities to accelerate the research, development, manufacturing, and commercialization of innovative cell immunotherapy products, improving patient access to high-quality therapies in China and worldwide.

JW Therapeutics has established an integrated platform spanning scientific discovery, process development, manufacturing, quality management, and clinical application. Focusing on hematologic malignancies, solid tumors, and autoimmune diseases, the Company continues to advance a differentiated pipeline while building robust commercial manufacturing capabilities and a comprehensive quality management system.

Guided by the vision of "Innovating cures, shaping what's next.", JW Therapeutics is committed to expanding access to high-quality cell immunotherapies and bringing new hope to patients in China and around the world.

*Juno Therapeutics is an innovative biotechnology company specializing in cell therapy research and development and is currently a wholly owned subsidiary of Bristol Myers Squibb (BMS).

1186 Clinical Response of CD19 CAR-T Cells (relmacabtagene autoleucel, relma-cel) in Adults with Heavily-Pre-Treated Relapsed/Refractory (r/r) Large B-Cell Lymphoma in China

The RELIANCE Trial provided the first demonstration of licensure-quality CAR-T manufacturing and clinical trial data generation in r/r patients originating in China. These results with relma-cel demonstrate similar preliminary response rates and PK profiles while providing the potential for an improved toxicity profile in heavily-pre-treated patients with r/r DLBCL having poor risk features relative to other CD19-specific CAR-Ts approved in the US and EU.

Comprehensive and differentiated cell therapy pipeline covering both hematological cancers and solid tumors

We have strategically built a comprehensive and differentiated product pipeline of cellular immunotherapy, covering a variety of next-generation approaches that improve the risk-to-benefit ratio of our products, including allogeneic approaches, combination strategies with small molecules and other CAR-T products with new gene modifications. We believe that our product candidates have the potential to be the ground-breaking therapies in their respective indications.

News Center

JW Therapeutics Announces NMPA Approval to Extend Cryopreservation Period of Sorted T Cells for Carteyva® to 36 Months, Further Enhancing CAR-T Manufacturing and Clinical Value

View All News...

Products

Process Development

Join Us